Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene

Genes Chromosomes and Cancer

Volumn 45, Issue 10, 2006, Pages 950-956

  Walz, Christoph ^a   Curtis, Claire ^b,c   Schnittger, Susanne ^d   Schultheis, Beate ^a   Metzgeroth, Georgia ^a   Schoch, Claudia ^d   Lengfelder, Eva ^a   Erben, Philipp ^a   Müller, Martin C ^a   Haferlach, Torsten ^d   Hochhaus, Andreas ^a   Hehlmann, Rüdiger ^a   Cross, Nicholas C P ^b,c   Reiter, Andreas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SALISBURY DISTRICT HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 5; IMATINIB; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR A; PROTEIN TYROSINE KINASE;

AGED; ARTICLE; CANCER REGRESSION; CASE REPORT; CDK5RAP2 GENE; CENTROSOME; CHROMOSOME 4Q; CHROMOSOME ANALYSIS; CHROMOSOME BAND; DIMERIZATION; DISEASE ASSOCIATION; EOSINOPHILIC LEUKEMIA; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE DISRUPTION; GENE MUTATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; HUMAN; INTRON; METAPHASE; MYELOPROLIFERATIVE DISORDER; ONCOGENE N RAS; PDGFRA GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT RESPONSE;

AGED; AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CHROMOSOMES, HUMAN, PAIR 4; CHROMOSOMES, HUMAN, PAIR 9; CHRONIC DISEASE; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPEREOSINOPHILIC SYNDROME; IN SITU HYBRIDIZATION, FLUORESCENCE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33748491495     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20359     Document Type: Article

References (48)

1. Abe A, Emi N, Tanimoto M, Terasaki H, Marunouchi T, Saito H. 1997. Fusion of the platelet-derived growth factor receptor-β to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution. Blood 90:4271-4277.
2. Ahuja H, Bar-Eli M, Arlin Z, Advani S, Allen SL, Goldman J, Snyder D, Foti A, Cline M. 1991. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J Clin Invest 87:2042-2047.
3. Baxter EJ, Hochhaus A, Bolufer P, Reiter A, Fernandez JM, Senent L, Cervera J, Moscardo F, Sanz MA, Cross NC. 2002. The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet 11:1391-1397.
4. Beaupre DM, Kurzrock R. 1999. RAS and leukemia: From basic mechanisms to gene-directed therapy. J Clin Oncol 17:1071-1079.
5. Bond J, Roberts E, Springell K, Lizarraga S, Scott S, Higgins J, Hampshire DJ, Morrison EE, Leal GF, Silva EO, Costa SM, Baralle D, Raponi M, Karbani G, Rashid Y, Jafri H, Bennett C, Corry P, Walsh CA, Woods CG. 2005. A centrosomal mechanism involving CDK5RAP2 and CENPJ controls brain size. Nat Genet 37:353-355.
6. Bousquet M, Quelen C, De Mas V, Duchayne E, Roquefeuil B, Delsol G, Laurent G, Dastugue N, Brousset P. 2005. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene 24:7248-7252.
7. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, Taylor K, Herrmann R, Seymour JF, Arthur C, Joske D, Lynch K, Hughes T. 2003. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102:276-283.
8. Ching YP, Qi Z, Wang JH. 2000. Cloning of three novel neuronal Cdk5 activator binding proteins. Gene 242:285-294.
9. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NCP, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG. 2003. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201-1214.
10. Cross NCP, Reiter A. 2002. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 16:1207-1212.
11. De Keersmaecker K, Cools J. 2006. Chronic myeloproliferative disorders: A tyrosine kinase tale. Leukemia 20:200-205.
12. Delaval B, Letard S, Lelievre H, Chevrier V, Daviet L, Dubreuil P, Birnbaum D. 2005. Oncogenic tyrosine kinase of malignant hemopathy targets the centrosome. Cancer Res 65:7231-7240.
13. Demiroglu A, Steer EJ, Heath C, Taylor K, Bentley M, Allen SL, Koduru P Brody JP, Hawson G, Rodwell R, Doody ML, Carnicero F, Reiter A, Goldman JM, Melo JV, Cross NC. 2001. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: Transforming activity and specific inhibition of FGFR1 fusion proteins. Blood 98:3778-3783.
14. Golub TR, Barker GF, Lovett M, Gilliland DG. 1994. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5:12) chromosomal translocation. Cell 77:307-316.
15. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. 2001. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880.
16. Hirsch-Ginsberg C, LeMaistre AC, Kantarjian H, Talpaz M, Cork A, Freireich EJ, Trujillo JM, Lee MS, Stass SA. 1990. RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood 76:1214-1219.
17. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, Hanfstein B, Schoch C, Cross N, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R. 2002. Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy. Leukemia 16:2190-2196.
18. Jones AV, Cross NC. 2004. Oncogenic derivatives of platelet-derived growth factor receptors. Cell Mol Life Sci 61:2912-2923.
19. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NC. 2005. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106:2162-2168.
20. Klion AD, Robyn J, Akin C, Noel P, Brown M, Law M, Metcalfe DD, Dunbar C, Nutman TB. 2004. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 103:473-478.
21. Krause DS, Van Etten RA. 2005. Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172-187.
22. Kulkarni S, Heath C, Parker S, Chase A, Iqbal S, Pocock CF, Kaeda J, Cwynarski K, Goldman JM, Cross NC. 2000. Fusion of H4/D10S170 to the platelet-derived growth factor receptor β in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33; q21). Cancer Res 60:3592-3598.
23. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, Berthou C, Lessard M, Berger R, Ghysdael J, Bernard OA. 1997. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278:1309-1312.
24. Macdonald D, Reiter A, Cross NCP. 2002. The 8p11 myeloproliferative syndrome: A distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 107:101-107.
25. Murati A, Gelsi-Boyer V, Adelaide J, Perot C, Talmant P, Giraudier S, Lode L, Letessier A, Delaval B, Brunel V, Imbert M, Garand R, Xerri L, Birnbaum D, Mozziconacci MJ, Chaffanet M. 2005. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation. Leukemia 19:1692-1696.
26. Nakao M, Janssen JW, Erz D, Seriu T, Bartram CR. 2000a. Tandem duplication of the FLT3 gene in acute lymphoblastic leukemia: A marker for the monitoring of minimal residual disease. Leukemia 14:522-524.
27. Nakao M, Janssen JW, Seriu T, Bartram CR. 2000b. Rapid and reliable detection of N-ras mutations in acuce lymphoblastic leukemia by melting curve analysis using LightCycler technology. Leukemia 14:312-315.
28. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, Reeder TL, Li CY, Cross NC, Cools J, Gilliland DG, Dewald GW, Tefferi A. 2003. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to Imatinib therapy. Blood 102:3093-3096.
29. Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyj AP, Elliott MA, Camoriano JK, Butterfield JH, Dewald GW, fefferi A. 2006. FIP1L1-PDGFRA in eosinophilic disorders: Prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 30:965-970.
30. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, Monpoux F, Van Rompaey L, Baens M, Van den BH, Marynen P. 1997. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15:12) in a myeloid leukemia. Blood 90:2535-2540.
31. Reiter A, Sohal J, Kulkarni S, Chase A, Macdonald DH, Aguiar RC, Goncalves C, Hernandez JM, Jennings BA, Goldman JM, Cross NC. 1998. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproiiferative syndrome. Blood 92:1735-1742.
32. Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, Berger U, Telford N, Aruliah S, Yin JA, Vanstraelen D, Barker HF, Taylor PC, O'Driscoll A, Benedetti F, Rudolph C, Kolb HJ, Hochhaus A, Hehlmann R, Chase A, Cross NC. 2005. The t(8;9)(p22; p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 65:2662-2667.
33. Safley AM, Sebastian S, Collins TS, Tirado CA, Stenzel TT, Gong JZ, Goodman BK. 2004. Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-α genes in a patient with atypical chronic myeloid leukemia. Genes Chromosomes Cancer 40:44-50.
34. Schnittger S, Kinkelin U, Schoch C, Heinecke A, Haase D, Haferlach T, Buchner T, Wormann B, Hiddemann W, Griesinger F. 2000. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia 14:796-804.
35. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, Loffler H, Sauerland CM, Serve H, Buchner T, Haferlach T, Hiddemann W. 2002. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: Correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100:59-66.
36. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, Haferlach T, Hiddemann W, Falini B. 2005. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 106:3733-3739.
37. Score J, Curtis C, Waghorn K, Stalder M, Jotterand M, Grand FH, Cross NC. 2006. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA ovetexpression in patients with hypereosinophilia. Leukemia 20:837-832.
38. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kutiyan J, Sawyers CL. 2002. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125.
39. Steer EJ, Cross NC. 2002. Myeloproliferative disorders with translocations of chromosome 5q31-35: Role of the platelet-derived growth factor receptor-β. Acta Haematol 107:113-122.
40. Stover EH, Cools J, Gilliland DG. 2004. Mechanisms of activation of the FIP1L1-PDGFRA fusion kinase. Blood 104:666a. [Abstract].
41. Suzuki M, Abe A, Kiyoi H, Murata M, Ito Y, Shimada K, Morishita Y, Kinoshita T, Naoe T. 2006. Mutations of N-RAS, FLT3 and p53 genes are not involved in the development of acute leukemia transformed from myeloproliferative diseases with JAK2 mutation. Leukemia 20:1168-1169.
42. Trempat P, Villalva C, Laurent G, Armstrong F, Delsol G, Dastugue N, Brousset P. 2003. Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor α receptor: A new clinical target for STI571/Glivec. Oncogene 22:5702-5706.
43. Tsurumi S, Nakamura Y, Maki K, Omine M, Fujita K, Okamura T, Niho Y, Hashimoto S, Kanno K, Suzuki K, Hangaishi A, Ogawa S, Hirai H, Mitani K. 2002. N-ras and p53 gene mutations in Japanese patients with myeloproliferative disorders. Am J Hematol 71:131-133.
44. Vandenberghe P, Wlodarska I, Michaux L, Zachee P, Boogaerts M, Vanstraelen D, Herregods MC, Van Hoof A, Selleslag D, Roufosse F, Maerevoet M, Verhoef G, Cools J, Gilliland DG, Hagemeijer A, Marynen P. 2004. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 18:734-742.
45. Vardiman JW, Harris NL, Brunning RD. 2002. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292-2302.
46. Walz C, Chase A, Schoch C, Weisser A, Schlegel F, Hochhaus A, Fuchs R, Schmitt-Graff A, Hehlmann R, Cross NC, Reiter A. 2005. The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1. Leukemia 19:1005-1009.
47. Wang X, Ching YR Lam WH, Qi Z, Zhang M, Wang JH. 2000. Identification of a common protein association region in the neuronal Cdk5 activator. J Biol Chem 275:31763-31769.
48. Watzinger F, Gaiger A, Karlic H, Becher R, Pillwein K, Lion T. 1994. Absence of N-ras mutations in myeloid and lymphoid blast crisis of chronic myeloid leukemia. Cancer Res 54:3934-3938.